RxDoctor Payments Data

Christopher Inhulsen, MD

Family Medicine · Oglethorpe, GANPI 1396788592

Payments from drug & device makers

$3,274in general payments, 2019–2025

Across 195 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$725
  • GSK$594
  • AstraZeneca$375
  • Boehringer Ingelheim$335
  • Lilly USA, LLC$319
  • Novartis$190
  • plus $737 from 15 others

What the payments were for

  • Food & beverage$3,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,274 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$15,857
Medicare patients
151
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$97,018
JardianceEmpagliflozin86$96,481
OzempicSemaglutide70$80,268
JanuviaSitagliptin Phosphate197$48,705
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$34,965
FarxigaDapagliflozin Propanediol52$34,645
MounjaroTirzepatide28$32,556
EntrestoSacubitril/Valsartan95$28,716
XareltoRivaroxaban122$26,006
LinzessLinaclotide42$25,376
Repatha SureclickEvolocumab13$9,511
Combivent RespimatIpratropium/Albuterol Sulfate16$8,958
Tresiba Flextouch U-200Insulin Degludec15$8,607
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$7,087
TradjentaLinagliptin52$6,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$335$112,325154 claims
Novo NordiskOzempic$725$80,26870 claims
MerckJanuvia$25$48,705197 claims
GSKTrelegy Ellipta$594$34,96530 claims
AstraZenecaFarxiga$375$34,64552 claims
Lilly USA, LLCMounjaro$319$32,55628 claims
AbbVieLinzess, Lumigan$96$29,07556 claims
NovartisEntresto$190$28,71695 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Oglethorpe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →